Dapirolizumab pegol Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Systemic Lupus Erythematosus A Phase 2b, randomized, double-blind, PBO-controlled, parallel-group, dose-ranging study followed by an observational period that will evaluate the efficacy of Dapirolizumab Pegol (DZP) in inducing disease control and the safety of DZP in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) who are receiving standard-of-care medications. Phase 2 SL0023 Completed NCT028047632015-004457-40 LINK Stach C., et al. Lupus Sci Med 2023; 10(Suppl 1):A163-A164 Post hoc analysis : Askanase A., et al. Arthritis Rheumatol 2023; 75(Suppl. 9):4622–4 Stach C., et al. Arthritis Rheumatol 2023; 75(Suppl. 9):2965–7 Cutcutache I., et al. Arthritis Rheumatol 2023; 75(Suppl. 9):4624–6 Systemic Lupus Erythematosus The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. Phase 3 SL0043 Completed NCT042946672019-003406-27 Systemic Lupus Erythematosus Placeholder (no action for Krankikom) Phase 3 SL0044 Ongoing NCT066173252019-003407-352023-508191-11-00 Systemic Lupus Erythematosus A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus Phase 3 SL0046 Ongoing NCT049763222019-003409-832023-506368-14-00
